Novo Nordisk's Multi-Pronged Defense: Patent Wins, Pill Studies, and a Buyback Machine
Published on 08/24/2026 at 13:43 | Redaktion boerse-global.de
The Danish pharmaceutical heavyweight is fighting its battle for the obesity market on several fronts at once — and the latest developments suggest a strategy built less on a single blockbuster moment and more on cumulative, defensive positioning.
At the center of that effort is a new late-stage clinical trial for the oral version of Wegovy. Launched on August 12, the study will enroll 450 participants across 62 sites in the US and Europe, with results expected by 2028. The goal: identifying the lowest effective dose of the tablet formulation. That granular approach stands in contrast to the "one-size-fits-all" race that competitor Eli Lilly appears to be running with its own oral candidates.
CEO Mike Doustdar made the company's thinking explicit in a Reuters interview on August 13. He argued that the obesity drug market isn't a contest any single player can dominate, and that investors are underestimating demand for differentiated products — tablets included. The timing of those remarks, coming just a day after the trial launch, was no accident.
A Legal Shield and a New US Launch
The company's legal team has been equally busy. In early August, a Dutch district court granted Novo Nordisk a preliminary injunction against Ceban Ziekenhuisfarmacie B.V., a compounding pharmacy that had been producing a semaglutide nasal spray allegedly infringing on the company's supplementary protection certificate. The court ordered Ceban to halt production, remove product listings, disclose supply chain information, and cover Novo Nordisk's legal fees. It's a notable victory in a market where copycat products are increasingly trying to tap into the surging demand for semaglutide-based treatments.
Around the same time, Novo Nordisk introduced Awiqli in the US market — another step in broadening its portfolio beyond the established injectables. And on August 10, the company announced a partnership with Amazon Web Services aimed at accelerating AI-driven drug discovery, with plans to establish a hub in London.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Buybacks: The Numbers Behind the Confidence
The financial machinery is also running at full tilt. Novo Nordisk's share repurchase program, launched in May, has a total volume of up to 11.2 billion Danish kroner and runs until February 1, 2027. As of August 14, the company had bought back 28,884,179 B-shares at an average price of 279.80 kroner — a total outlay of roughly 8.08 billion kroner. That leaves the company holding 42,924,876 treasury B-shares, equivalent to 1.0 percent of share capital.
In a separate transaction disclosed on August 17, the company reported purchasing 200,000 B-shares on August 10 at an average price of 303.97 kroner, worth approximately 60.8 million kroner. The stock also went ex-dividend on August 14, with a payout of 3.75 kroner per share.
A Stock Still Climbing Back
The market's response has been cautiously positive. The shares closed Friday at 39.98 euros, up 1.0 percent on the day and 2.9 percent for the week. More recent trading shows the stock at 40.27 euros, 0.7 percent above the prior session and 3.6 percent higher week-over-week.
But the longer-term picture remains challenging. The stock is down 9.2 percent year-to-date and 18 percent over the past twelve months. It sits 27 percent below its 52-week high of 54.86 euros, reached in late January.
The recent stabilization coincides with the flurry of news around the pill trial, Doustdar's competitive commentary, and the ongoing buyback activity — suggesting investors are beginning to credit the company's broader strategy, even if the shares remain deep in the red for the year.
For now, Novo Nordisk's playbook is clear: defend intellectual property aggressively, keep buying back stock, and build out a pipeline that offers more than just one route to weight loss. Whether that combination will be enough to close the gap with its rivals — and recover the ground lost since January's peak — will ultimately depend on how the competitive dynamics in the GLP-1 market evolve.
Ad
Novo Nordisk Stock: New Analysis - 24 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
